GeoVax to Exhibit at the 2009 BIO International Convention

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

ATLANTA, May 11 /PRNewswire-FirstCall/ --

WHAT: GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based,
publicly traded biopharmaceutical company developing human
vaccines for diseases caused by HIV-1 (Human Immunodeficiency
Virus) and other infectious agents to share their strategy for
the future and plans to expand preventative trials, currently in
Phase 2a, to proof-of-concept trials in 'at risk' humans and
move therapeutic trials from non-human primate models to HIV-1
virus infected individuals.

Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative
and Therapeutic Approaches to a Global Pandemic"

WHERE: 2009 BIO International Convention
Georgia Pavilion (Booth #2817)
Georgia World Congress Center
Atlanta, GA

WHEN: May 18-21, 2009
"HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a
Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309

WHO: Robert McNally, Ph.D., chief executive officer and president
Mark Reynolds, chief financial officer
Harriet Robinson, PhD, vice president of research and development
and developer of the GeoVax vaccine

WHY: HIV Vaccine Awareness Day coincides with the opening of the
conference on May 18, and Sir Elton John delivering a keynote
address to include how biotechnology is influencing treatment and
prevention of the diseases. GeoVax is looking forward to sharing
with interested partners, investors and media its progress in
clinical trials during the last six months and its strategy for
the future.

SOURCE GeoVax Labs, Inc.

Bob McNally of GeoVax, +1-404-727-0971, bmcnally@geovax.com; or Leslie Loyet
of Financial Relations Board, +1-312-640-6672, lloyet@mww.com, for GeoVax